文献速递心力衰竭与心肌病心律失常

联合心肌病与心律失常基因检测诊断率评估

Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing.
PubMed 文献 · JAMA Cardiol · 2022-01-01

这项回顾性队列研究分析了4782例疑似遗传性心肌病或心律失常患者接受联合基因检测的结果,发现19.9%的患者获得阳性分子诊断,其中66.0%的阳性结果可能影响临床管理。若仅检测高怀疑患者或按临床诊断限制面板,将遗漏部分阳性结果。

要点

  • 联合检测在疑似患者中阳性诊断率为19.9%。
  • 66.0%阳性结果可指导管理或监测。
  • 限制检测会遗漏部分阳性发现。

核心结论

  • 联合心肌病与心律失常基因检测可发现疾病特异性检测遗漏的诊断。

研究设计与样本

  • 回顾性队列研究,纳入4782例疑似遗传性心肌病或心律失常患者,由1203名临床医生转诊,2019年7月12日至2020年7月9日在一家检测机构接受免费赞助检测。

主要发现

  • 4782例患者中954例(19.9%)获得阳性分子诊断。
  • 630例阳性患者(66.0%)的結果可能影响临床管理。
  • 若仅检测高怀疑患者,至少137例阳性结果(14.4%)会被遗漏。
  • 若按临床诊断限制面板,75/689例阳性结果(10.9%)会被遗漏,其中27/75例(36.0%)为心肌病指征伴心律失常基因发现或反之。
  • 家族级联检测产生402/958例阳性结果(42.0%)。

关键数值与推荐

  • 4782例患者中2446例(51.2%)仅携带意义不明确变异。
  • 致心律失常性心肌病转诊患者意义不明确变异率最低(81/176例,46.0%)。
  • 儿茶酚胺敏感性多形性室速转诊患者意义不明确变异率最高(48/76例,63.2%)。

临床怎么用

  • 对疑似遗传性心肌病或心律失常患者可考虑联合基因检测以提高诊断率。
  • 联合检测结果可能为患者及家属提供管理或监测依据。

局限性

  • 研究为回顾性设计,且检测为免费赞助项目,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genetic testing can guide management of both cardiomyopathies and arrhythmias, but cost, yield, and uncertain results can be barriers to its use. It is unknown whether combined disease testing can improve diagnostic yield and clinical utility for patients with a suspected genetic cardiomyopathy or arrhythmia. OBJECTIVE: To evaluate the diagnostic yield and clinical management implications of combined cardiomyopathy and arrhythmia genetic testing through a no-charge, sponsored program for patients with a suspected genetic cardiomyopathy or arrhythmia. DESIGN, SETTING, AND PARTICIPANTS: This cohort study involved a retrospective review of DNA sequencing results for cardiomyopathy- and arrhythmia-associated genes. The study included 4782 patients with a suspected genetic cardiomyopathy or arrhythmia who were referred for genetic testing by 1203 clinicians; all patients participated in a no-charge, sponsored genetic testing program for cases of suspected genetic cardiomyopathy and arrhythmia at a single testing site from July 12, 2019, through July 9, 2020. MAIN OUTCOMES AND MEASURES: Positive gene findings from combined cardiomyopathy and arrhythmia testing were compared with findings from smaller subtype-specific gene panels and clinician-provided diagnoses. RESULTS: Among 4782 patients (mean [SD] age, 40.5 [21.3] years; 2551 male [53.3%]) who received genetic testing, 39 patients (0.8%) were Ashkenazi Jewish, 113 (2.4%) were Asian, 571 (11.9%) were Black or African American, 375 (7.8%) were Hispanic, 2866 (59.9%) were White, 240 (5.0%) were of multiple races and/or ethnicities, 138 (2.9%) were of other races and/or ethnicities, and 440 (9.2%) were of unknown race and/or ethnicity. A positive result (molecular diagnosis) was confirmed in 954 of 4782 patients (19.9%). Of those, 630 patients with positive results (66.0%) had the potential to inform clinical management associated with adverse clinical outcomes, increased arrhythmia risk, or targeted therapies. Combined cardiomyopathy and arrhythmia gene panel testing identified clinically relevant variants for 1 in 5 patients suspected of having a genetic cardiomyopathy or arrhythmia. If only patients with a high suspicion of genetic cardiomyopathy or arrhythmia had been tested, at least 137 positive results (14.4%) would have been missed. If testing had been restricted to panels associated with the clinician-provided diagnostic indications, 75 of 689 positive results (10.9%) would have been missed; 27 of 75 findings (36.0%) gained through combined testing involved a cardiomyopathy indication with an arrhythmia genetic finding or vice versa. Cascade testing of family members yielded 402 of 958 positive results (42.0%). Overall, 2446 of 4782 patients (51.2%) had only variants of uncertain significance. Patients referred for arrhythmogenic cardiomyopathy had the lowest rate of variants of uncertain significance (81 of 176 patients [46.0%]), and patients referred for catecholaminergic polymorphic ventricular tachycardia had the highest rate (48 of 76 patients [63.2%]). CONCLUSIONS AND RELEVANCE: In this study, comprehensive genetic testing for cardiomyopathies and arrhythmias revealed diagnoses that would have been missed by disease-specific testing. In addition, comprehensive testing provided diagnostic and prognostic information that could have potentially changed management and monitoring strategies for patients and their family members. These results suggest that this improved diagnostic yield may outweigh the burden of uncertain results.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Dellefave-Castillo LM, Cirino AL, Callis TE, et al. Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic Testing. JAMA Cardiol. 2022. PMID: 35947370. doi:10.1001/jamacardio.2022.2455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。